Resources

IMpassion031: Results from a phase III study of neoadjuvant atezolizumab + chemotherapy in early triple-negative breast cancer (TNBC).

IMbrave150: Management of Adverse Events of Special Interest (AESIs) for Atezolizumab and Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma (HCC)

Characterisation of long-term survivors treated with first line chemotherapy ± atezolizumab in extensive-stage small cell lung cancer.

HRD/gLOH new biomarkers: Pan-cancer analysis of homologous recombination repair-associated alterations and genome-wide loss of heterozygosity.

Patient-reported outcomes from IMvigor130: a Phase III trial comparing atezolizumab + platinum-based chemotherapy to placebo + platinum-based chemotherapy in untreated advanced urothelial carcinoma

FIRST-LINE Systemic Therapies in Advanced HCC.
SECOND-LINE Systemic Therapies in Advanced HCC.
Systemic and Loco-Regional COMBINATIONS in Advanced HCC.